The present disclosure relates to methods of treating epilepsy, cancer, and post-operative pain in veterinary subjects using pharmaceutical compositions and dosage forms comprising hemp extract.

The present disclosure relates to methods of treating epilepsy, cancer, and post-operative pain in veterinary subjects using pharmaceutical compositions and dosage forms comprising hemp extract.

Inhibition of EphB receptors (e.g., EphB1) can be used in therapeutic methods for treating EphB receptor-associated conditions (e.g., pain, cancer). Demeclocycline, chlortetracycline, and minocycline are identified as EphB receptor inhibitors. Accordingly, aspects of the disclosure relate to methods for treating pain comprising providing demeclocycline, chlortetracycline, minocycline, or derivatives thereof, alone or in combination, to an individual in need thereof. Further aspects relate to pharmaceutical compositions comprising two or more of minocycline, demeclocycline, chlortetracycline, and/or derivatives thereof.

##STR00001##

Inhibition of EphB receptors (e.g., EphB1) can be used in therapeutic methods for treating EphB receptor-associated conditions (e.g., pain, cancer). Demeclocycline, chlortetracycline, and minocycline are identified as EphB receptor inhibitors. Accordingly, aspects of the disclosure relate to methods for treating pain comprising providing demeclocycline, chlortetracycline, minocycline, or derivatives thereof, alone or in combination, to an individual in need thereof. Further aspects relate to pharmaceutical compositions comprising two or more of minocycline, demeclocycline, chlortetracycline, and/or derivatives thereof.

##STR00001##

Inhibition of EphB receptors (e.g., EphB1) can be used in therapeutic methods for treating EphB receptor-associated conditions (e.g., pain, cancer). Demeclocycline, chlortetracycline, and minocycline are identified as EphB receptor inhibitors. Accordingly, aspects of the disclosure relate to methods for treating pain comprising providing demeclocycline, chlortetracycline, minocycline, or derivatives thereof, alone or in combination, to an individual in need thereof. Further aspects relate to pharmaceutical compositions comprising two or more of minocycline, demeclocycline, chlortetracycline, and/or derivatives thereof.

##STR00001##

A disinfecting composition may contain 0.001 to 5 mass % of an MPC copolymer containing a constituent unit based on 2-(meth)acryloyloxyethyl phosphorylcholine, 5 to 90 mass % of a lower alcohol, and 0.01 to 10 mass % of an aliphatic acid ester-based nonionic surfactant. The MPC copolymer may include one or more copolymer selected from of an MPC copolymer a having a weight average molecular weight of 10,000 to 400,000 and an MPC copolymer b having a weight average molecular weight of 800,000 to 1,800,000. Such a disinfecting composition may be excellent in foam sustainability when it is discharged as a foam and that has moist feeling when it is applied.

A method of purifying cannabis derived terpenes includes first providing cannabis material having a detectable amount of tetrahydrocannabinolic acid (THCA), adding a solvent to the cannabis material, spinning the cannabis material in a centrifuge to separate crystallized THCA from a high terpene extract. Decarboxilating the THCA with heat to yield tetrahydrocannabinol. The high terpene extract is deposited into a vacuum oven to reduce pressure and volatilize terpenes from the high terpene extract. Next the terpenes are pumped into a cold trap to condense terpenes from the high terpene extract. Next, the condensed terpenes are cooled at a temperature between −50° C. and 0° C. to remove water from the condensed terpenes and yield purified terpenes. The purified terpenes are applied to an edible food product containing decarboxylated tetrahydrocannabinol. In an alternate embodiment, the tetrahydrocannabinol and the purified terpenes are combined or recombined and mixed directly into a precooked edible food product.

A method of purifying cannabis derived terpenes includes first providing cannabis material having a detectable amount of tetrahydrocannabinolic acid (THCA), adding a solvent to the cannabis material, spinning the cannabis material in a centrifuge to separate crystallized THCA from a high terpene extract. Decarboxilating the THCA with heat to yield tetrahydrocannabinol. The high terpene extract is deposited into a vacuum oven to reduce pressure and volatilize terpenes from the high terpene extract. Next the terpenes are pumped into a cold trap to condense terpenes from the high terpene extract. Next, the condensed terpenes are cooled at a temperature between −50° C. and 0° C. to remove water from the condensed terpenes and yield purified terpenes. The purified terpenes are applied to an edible food product containing decarboxylated tetrahydrocannabinol. In an alternate embodiment, the tetrahydrocannabinol and the purified terpenes are combined or recombined and mixed directly into a precooked edible food product.

An antibacterial antiviral pharmaceutical composition, comprising the following raw materials in parts by weight: 4-14 parts of Herba pogostemonis, 9-28 parts of Rhizoma atractylodis, 5-18 parts of Herba elshoitziae, 11-33 parts of Folium artemisiae argyi, 0.1-3 parts of Flos caryophylli, and 2-10 parts of Herba menthae, and further comprising natural borneol and pharmaceutical adjuvants. The pharmaceutical composition can be prepared into medicinal volatile oil. The pharmaceutical composition and the volatile oil thereof can be used for resisting bacteria and viruses, clearing heat, reducing fever and/or treating respiratory diseases, and can be applied to the preparation of medicines for resisting SARS-CoV-2.

An antibacterial antiviral pharmaceutical composition, comprising the following raw materials in parts by weight: 4-14 parts of Herba pogostemonis, 9-28 parts of Rhizoma atractylodis, 5-18 parts of Herba elshoitziae, 11-33 parts of Folium artemisiae argyi, 0.1-3 parts of Flos caryophylli, and 2-10 parts of Herba menthae, and further comprising natural borneol and pharmaceutical adjuvants. The pharmaceutical composition can be prepared into medicinal volatile oil. The pharmaceutical composition and the volatile oil thereof can be used for resisting bacteria and viruses, clearing heat, reducing fever and/or treating respiratory diseases, and can be applied to the preparation of medicines for resisting SARS-CoV-2.